含遗传灭活百日咳毒素的重组百日咳加强疫苗在孕妇中的2期随机对照剂量探索试验
在健康泰国孕妇中开展2期随机观察者盲法活性对照非劣效试验,400名孕妇分别接种含1µg PTgen和1µg FHA的ap1gen、Tdap1gen、Tdap2gen、TdaP5gen或含8µg化学灭活百日咳类毒素的Tdap8chem,结合250名非孕妇数据,所有含PTgen疫苗对Tdap8chem非劣效,ap1gen和TdaP5gen可被认为免疫原性优效,各组局部和全身征集性反应相似。
要点
- 含PTgen的疫苗在孕妇中安全且有免疫原性。
- 所有含PTgen研究疫苗对Tdap8chem非劣效。
- ap1gen和TdaP5gen可被认为对Tdap8chem免疫原性优效。
核心结论
- 含PTgen的疫苗制剂在孕妇中安全且有免疫原性。
- ap1gen疫苗成本最低、反应原性最低,当不需要白喉和破伤风类毒素时可能适合孕妇使用。
研究设计与样本
- 2期随机、观察者盲法、活性对照非劣效试验,在健康泰国孕妇中开展。
- 400名健康孕妇随机接受一剂ap1gen、Tdap1gen、Tdap2gen、TdaP5gen或Tdap8chem。
- 于第0天和第28天采集血液,非劣效性基于第28天抗PT IgG抗体水平,并与先前结构相似的非孕妇试验结果合并评估。
主要发现
- 结合250名非孕妇数据,所有含PTgen研究疫苗对Tdap8chem非劣效。
- ap1gen和TdaP5gen疫苗可被认为对Tdap8chem免疫原性优效。
- 所有疫苗组局部和全身征集性反应相似。
关键数值与推荐
- ap1gen含1µg PTgen和1µg FHA。
- Tdap1gen为破伤风、减量白喉联合ap1gen。
- Tdap2gen含2µg PTgen和5µg FHA。
- TdaP5gen(Boostagen®)含5µg PTgen和5µg FHA。
- 对照疫苗Tdap8chem(Boostrix™)含8µg化学灭活百日咳类毒素、8µg FHA和2.5µg百日咳杆菌黏附素。
临床怎么用
- 尽管COVID-19大流行导致百日咳杆菌感染减少,仍推荐孕妇加强接种以保护新生儿。
- ap1gen疫苗成本最低、反应原性最低,当不需要白喉和破伤风类毒素时可能适合孕妇使用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite a decrease in infections caused by Bordetella pertussis due to COVID-19 pandemic, booster vaccination of pregnant women is still recommended to protect newborns. Highly immunogenic vaccines containing genetically inactivated pertussis toxin (PTgen) and filamentous hemagglutinin (FHA) may generate comparable anti-PT antibody concentrations, even at lower doses, to chemically inactivated acellular pertussis vaccines (Tdapchem) shown effective for maternal immunization. METHODS: This phase 2 randomized, observer-blind, active-controlled non-inferiority trial was conducted in healthy Thai pregnant women randomly assigned to receive one dose of low-dose recombinant pertussis-only vaccine containing 1 µg PTgen and 1 µg FHA (ap1gen), or tetanus, reduced-dose diphtheria combined with ap1gen (Tdap1gen), or combined with 2 µg PTgen and 5 µg FHA (Tdap2gen), or with 5 µg PTgen and 5 µg FHA (TdaP5gen, Boostagen®) or comparator containing 8 µg of chemically inactivated pertussis toxoid, 8 µg FHA, and 2.5 µg pertactin (Boostrix™, Tdap8chem). Blood was collected at Day 0 and Day 28 post-vaccination. The non-inferiority of the study vaccines was assessed based on anti-PT IgG antibody levels on Day 28 pooled with results from a similarly structured previous trial in non-pregnant women. RESULTS: 400 healthy pregnant women received one dose of vaccine. Combined with data from 250 non-pregnant women, all study vaccines containing PTgen were non-inferior to comparator vaccine (Tdap8chem). Both ap1gen and TdaP5gen vaccines could be considered to have superior immunogenicity to Tdap8chem. Local and systemic solicited reactions were similar among all vaccine groups. CONCLUSIONS: Vaccine formulations containing PTgen were safe and immunogenic in pregnant women. The ap1gen vaccine, with the lowest cost and reactogenicity, may be suitable for use in pregnant women when diphtheria and tetanus toxoids are not needed. This study is registered in the Thai Clinical Trial Registry (www. CLINICALTRIALS: in.th), number TCTR20180725004.
引用
- Puthanakit T, Chokephaibulkit K, Chaithongwongwatthana S, et al. A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women. Vaccine. 2023. PMID: 37330371. doi:10.1016/j.vaccine.2023.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。